Skip to content
Home/Companies/Biotech/Myelo Therapeutics

Myelo Therapeutics

Biotech·Germany·Exited 2020·Held 7yr
Entry
2013
Hold
7yr
Exit
2020

Who owns Myelo Therapeutics?

Myelo Therapeutics was owned by IBB Ventures through VC Fonds Technologie Berlin (1997 vintage) from 2013 to 2020, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-10

IBB Ventures
Investor
IBB Ventures
VC Fonds Technologie Berlin · 1997 · VC

Key facts

HQGermany
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2020

More from VC Fonds Technologie Berlin

Other portfolio companies in the same fund.

Bounti
Bounti
Active
SoftwareGermany· 2026
hellomed
Active
HealthTechGermany· 2026
Level Nine
Active
ClimateTechGermany· 2026
Nox Mobility
Nox Mobility
Active
MobilityGermany· 2026
Remi Health
Remi Health
Active
HealthTechGermany· 2026
Amara
Active
HealthTechGermany· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Myelo Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Myelo Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue